In Search Of A Stimulant Use Disorder Treatment: ‘We’ve Been Doing It Wrong’
US FDA official questions whether problem is due to population selection, outcome measures, or study duration. Potential endpoints include change in disease status as measured by DSM-5 criteria, cognitive function and quality of life, experts say.
